[go: up one dir, main page]
Wikipedia

Biomarker (medicine)

For other uses, see Biomarker (disambiguation).

In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."[1] More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.[2]

A biomarker can be a substance that is introduced into an organism as a means to examine organ function or other aspects of health. For example, rubidium chloride is used in isotopic labeling to evaluate perfusion of heart muscle. It can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection. More specifically, a biomarker indicates a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment. Biomarkers can be characteristic biological properties or molecules that can be detected and measured in parts of the body like the blood or tissue. They may indicate either normal or diseased processes in the body.[3] Biomarkers can be specific cells, molecules, or genes, gene products, enzymes, or hormones. Complex organ functions or general characteristic changes in biological structures can also serve as biomarkers. Although the term biomarker is relatively new, biomarkers have been used in pre-clinical research and clinical diagnosis for a considerable time.[4] For example, body temperature is a well-known biomarker for fever. Blood pressure is used to determine the risk of stroke. It is also widely known that cholesterol values are a biomarker and risk indicator for coronary and vascular disease, and that C-reactive protein (CRP) is a marker for inflammation.

Biomarkers are useful in a number of ways, including measuring the progress of disease, evaluating the most effective therapeutic regimes for a particular cancer type, and establishing long-term susceptibility to cancer or its recurrence.[5] Biomarkers characterize disease progression starting from the earliest natural history of the disease. Biomarkers assess disease susceptibility and severity, which allows one to predict outcomes, determine interventions and evaluate therapeutic responses. From a forensics and epidemiologic perspective, biomarkers offer unique insight about the relationships between environmental risk factors.[1] The parameter can be chemical, physical or biological. In molecular terms biomarker is "the subset of markers that might be discovered using genomics, proteomics technologies or imaging technologies. Biomarkers play major roles in medicinal biology. Biomarkers help in early diagnosis, disease prevention, drug target identification, drug response etc. Several biomarkers have been identified for many diseases such as serum LDL for cholesterol, blood pressure, and P53 gene[6] and MMPs [7] as tumor markers for cancer.

edit

It is necessary to distinguish between disease-related and drug-related biomarkers. Disease-related biomarkers give an indication of the probable effect of treatment on patient (risk indicator or predictive biomarkers), if a disease already exists (diagnostic biomarker), or how such a disease may develop in an individual case regardless of the type of treatment (prognostic biomarker). Predictive biomarkers help to assess the most likely response to a particular treatment type, while prognostic markers shows the progression of disease with or without treatment.[8] In contrast, drug-related biomarkers indicate whether a drug will be effective in a specific patient and how the patient's body will process it.

In addition to long-known parameters, such as those included and objectively measured in a blood count, there are numerous novel biomarkers used in the various medical specialties. Currently, intensive work is taking place on the discovery and development of innovative and more effective biomarkers. These "new" biomarkers have become the basis for preventive medicine, meaning medicine that recognises diseases or the risk of disease early, and takes specific countermeasures to prevent the development of disease. Biomarkers are also seen as the key to personalised medicine, treatments individually tailored to specific patients for highly efficient intervention in disease processes. Often, such biomarkers indicate changes in metabolic processes.

The "classic" biomarker in medicine is a laboratory parameter that the doctor can use to help make decisions in making a diagnosis and selecting a course of treatment. For example, the detection of certain autoantibodies in patient blood is a reliable biomarker for autoimmune disease, and the detection of rheumatoid factors has been an important diagnostic marker for rheumatoid arthritis (RA) for over 50 years.[9][10] For the diagnosis of this autoimmune disease the antibodies against the bodies own citrullinated proteins are of particular value. These ACPAs, (ACPA stands for Anti-citrullinated protein/peptide antibody) can be detected in the blood before the first symptoms of RA appear. They are thus highly valuable biomarkers for the early diagnosis of this autoimmune disease.[11] In addition, they indicate if the disease threatens to be severe with serious damage to the bones and joints,[12][13] which is an important tool for the doctor when providing a diagnosis and developing a treatment plan.

There are also more and more indications that ACPAs can be very useful in monitoring the success of treatment for RA.[14] This would make possible the accurate use of modern treatments with biologicals. Physicians hope to soon be able to individually tailor rheumatoid arthritis treatments for each patient.

According to Häupl T. et al. prediction of response to treatment will become the most important aim of biomarker research in medicine. With the growing number of new biological agents, there is increasing pressure to identify molecular parameters such as ACPAs that will not only guide the therapeutic decision but also help to define the most important targets for which new biological agents should be tested in clinical studies.[15]

An NIH study group committed to the following definition in 1998: "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." In the past, biomarkers were primarily physiological indicators such as blood pressure or heart rate. More recently, biomarker is becoming a synonym for molecular biomarker, such as elevated prostate specific antigen as a molecular biomarker for prostate cancer, or using enzyme assays as liver function tests. There has recently been heightened interest in the relevance of biomarkers in oncology, including the role of KRAS in colorectal cancer and other EGFR-associated cancers. In patients whose tumors express the mutated KRAS gene, the KRAS protein, which forms part of the EGFR signaling pathway, is always 'turned on'. This overactive EGFR signaling means that signaling continues downstream – even when the upstream signaling is blocked by an EGFR inhibitor, such as cetuximab (Erbitux) – and results in continued cancer cell growth and proliferation. Testing a tumor for its KRAS status (wild-type vs. mutant) helps to identify those patients who will benefit most from treatment with cetuximab.

Currently, effective treatment is available for only a small percentage of cancer patients. In addition, many cancer patients are diagnosed at a stage where the cancer has advanced too far to be treated. Biomarkers have the ability to greatly enhance cancer detection and the drug development process. In addition, biomarkers will enable physicians to develop individualized treatment plans for their cancer patients; thus allowing doctors to tailor drugs specific to their patient's tumor type. By doing so, drug response rate will improve, drug toxicity will be limited and costs associated with testing various therapies and the ensuing treatment for side effects will decrease.[16]

Biomarkers also cover the use of molecular indicators of environmental exposure in epidemiologic studies such as human papilloma virus or certain markers of tobacco exposure such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). To date no biomarkers have been established for head and neck cancer.

Biomarker requirements

edit

For chronic diseases, whose treatment may require patients to take medications for years, accurate diagnosis is particularly important, especially when strong side effects are expected from the treatment. In these cases, biomarkers are becoming more and more important, because they can confirm a difficult diagnosis or even make it possible in the first place.[17] A number of diseases, such as Alzheimer's disease or rheumatoid arthritis, often begin with an early, symptom-free phase. In such symptom-free patients there may be more or less probability of actually developing symptoms. In these cases, biomarkers help to identify high-risk individuals reliably and in a timely manner so that they can either be treated before onset of the disease or as soon as possible thereafter.[18][19]

In order to use a biomarker for diagnostics, the sample material must be as easy to obtain as possible. This may be a blood sample taken by a doctor, a urine or saliva sample, or a drop of blood like those diabetes patients extract from their own fingertips for regular blood-sugar monitoring.

For rapid initiation of treatment, the speed with which a result is obtained from the biomarker test is critical. A rapid test, which delivers a result after only a few minutes, is optimal. This makes it possible for the physician to discuss with the patient how to proceed and if necessary to start treatment immediately after the test.

Naturally, the detection method for a biomarker must be accurate and as easy to carry out as possible. The results from different laboratories may not differ significantly from each other, and the biomarker must naturally have proven its effectiveness for the diagnosis, prognosis, and risk assessment of the affected diseases in independent studies.

A biomarker for clinical use needs good sensitivity and specificity e.g. ≥0.9, and good specificity e.g. ≥0.9[20] although they should be chosen with the population in mind so positive predictive value and negative predictive value are more relevant.

Biomarker classification and application

edit

Biomarkers can be classified based on different criteria.

Based on their characteristics they can be classified as imaging biomarkers (CT, PET, MRI) or molecular biomarkers with three subtypes: volatile, like breath,[21] body fluid, or biopsy biomarkers.

Molecular biomarkers refer to non-imaging biomarkers that have biophysical properties, which allow their measurements in biological samples (e.g., plasma, serum, cerebrospinal fluid, bronchoalveolar lavage, biopsy) and include nucleic acids-based biomarkers such as gene mutations or polymorphisms and quantitative gene expression analysis, peptides, proteins, lipids metabolites, and other small molecules.

Biomarkers can also be classified based on their application such as diagnostic biomarkers (i.e., cardiac troponin for the diagnosis of myocardial infarction), staging of disease biomarkers (i.e., brain natriuretic peptide for congestive heart failure), disease prognosis biomarkers (cancer biomarkers), and biomarkers for monitoring the clinical response to an intervention (HbAlc for antidiabetic treatment). Another category of biomarkers includes those used in decision making in early drug development. For instance, pharmacodynamic (PD) biomarkers are markers of a certain pharmacological response, which are of special interest in dose optimization studies.

Classes

edit

Four broad classes of biomarkers are diagnostic biomarkers, prognostic biomarkers, predictive biomarkers and pharmacodynamic biomarkers.

Diagnostic

edit

Diagnostic biomarkers give intervention-independent information on identifying or aid in identifying if there is a presence or absence of the disease or a disease subcategory/subphenotype status.[22] An example is the traumatic brain injury (TBI) blood-based biomarker test consisted of measuring the levels of neuronal Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP) to aid in the diagnosis of the presence of cranial lesion(s) among moderate to mild TBI patients that is(are) otherwise only diagnosable with the use of a CT scan of the head.[23]

Prognostic

edit

Prognostic biomarkers give intervention-independent information on disease status and outcome prediction. Prognostic biomarkers can signify individuals in the latent period of a disease's natural history, allowing optimal therapy and prevention until the disease's termination. Prognostic biomarkers give information on disease status by measuring the internal precursors that increase or decrease the likelihood of attaining a disease. For example, blood pressure and cholesterol are biomarkers for CVD.[1] Prognostic biomarkers can be direct or indirect to the causal pathway of a disease. If a prognostic biomarker is a direct step in the causal pathway, it is one of the factors or products of the disease. A prognostic biomarker could be indirectly associated with a disease if it is related to a change caused by the exposure, or related to an unknown factor connected with the exposure or disease.[24]

Predictive

edit

Predictive biomarkers measure the effect of a drug and tell if the drug is having its expected activity, but do not offer any direct information on the disease.[24] Predictive biomarkers are highly sensitive and specific; therefore they increase diagnostic validity of a drug or toxin's site-specific effect by eliminating recall bias and subjectivity from those exposed. For example, when an individual is exposed to a drug or toxin, the concentration of that drug or toxin within the body, or the biological effective dose, provides a more accurate prediction for the effect of the drug or toxin compared to an estimation or measurement of the toxin from the origin or external environment.[1]

Pharmacodynamic

edit

Pharmacodynamic (PD) biomarkers can measure the direct interaction between a drug and its receptor. Pharmacodynamic biomarkers reveal drug mechanisms, if the drug has its intended effect on the biology of the disease, ideal biological dosing concentrations, and physiologic response/resistance mechanisms. Pharmacodynamic biomarkers are particularly relevant in drug mechanisms of tumor cells, where pharmacodynamic endpoints for drug interventions can be assessed directly on tumor tissues. For example, protein phosphorylation biomarkers indicate alterations in target protein kinases and activation of downstream signaling molecules.[25]

Types

edit

Biomarkers validated by genetic and molecular biology methods can be classified into three types.[26]

  • Type 0 — Natural history markers
  • Type 1 — Drug activity markers
  • Type 2 — Surrogate markers

Discovery of molecular biomarkers

edit
Main article: Biomarker discovery

Molecular biomarkers have been defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. Many genomic and proteomics techniques are available for biomarker discovery and a few techniques that are recently being used can be found on that page. Apart from genomics and proteomics platforms biomarker assay techniques, metabolomics, lipidomics, glycomics, and secretomics are the most commonly used as techniques in identification of biomarkers.

Clinical applications

edit

Biomarkers can be classified on their clinical applications as molecular biomarkers, cellular biomarkers or imaging biomarkers.

Molecular

edit

Four of the main types of molecular biomarkers are genomic biomarkers, transcriptomic biomarkers, proteomic biomarkers and metabolic biomarkers.

Genomic

edit

Genomic biomarkers analyze DNA by identifying irregular sequences in the genome, typically a single nucleotide polymorphism. Genetic biomarkers are particularly significant in cancer because most cancer cell lines carry somatic mutations. Somatic mutations are distinguishable from hereditary mutations because the mutation is not in every cell; just the tumor cells, making them easy targets.

Transcriptomic

edit

Transcriptomic biomarkers analyze all RNA molecules, not solely the exome. Transcriptomic biomarkers reveal the molecular identity and concentration of RNA in a specific cell or population. Pattern-based RNA expression analysis provides increased diagnostic and prognostic capability in predicting therapeutic responses for individuals. For example, distinct RNA subtypes in breast cancer patients have different survival rates.[27]

Proteomic

edit

Proteomics permits the quantitative analysis and detection of changes to proteins or protein biomarkers. Protein biomarkers detect a variety of biological changes, such as protein-protein interactions, post-translational modifications and immunological responses.

Cellular

edit

Cellular biomarkers allow cells to be isolated, sorted, quantified and characterized by their morphology and physiology. Cellular biomarkers are used in both clinical and laboratory settings, and can discriminate between a large sample of cells based on their antigens. An example of a cellular biomarker sorting technique is Fluorescent-activated cell sorting.[28]

Blood-based protein biomarkers

edit

Blood-based protein biomarkers are commonly used in diagnostic tests to monitor one or more proteins indicative of the presence of a disease, disorder, or specific disease subphenotype. These biomarkers can also serve as prognosticators, providing valuable insights into disease outcomes. An example is neuronal Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP) can aid in the diagnosis of the presence a cranial lesion among moderate to mild TBI patients that is otherwise only diagnosable with the use of a CT scan of the head.[29]

Imaging biomarkers

edit
Main article: Imaging biomarker

Imaging biomarkers allow earlier detection of disease compared to molecular biomarkers, and streamline translational research in the drug discovery marketplace. For example, one could determine the percent of receptors a drug targets, shortening the time and money of research during the new drug development stage. Imaging biomarkers also are non-invasive, which is a clinical advantage over molecular biomarkers. Some of the image-based biomarkers are X-Ray, Computed Tomography (CT), Positron Emission Tomography (PET), Single Photo Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI).[30]

Many new biomarkers are being developed that involve imaging technology. Imaging biomarkers have many advantages. They are usually noninvasive, and they produce intuitive, multidimensional results. Yielding both qualitative and quantitative data, they are usually relatively comfortable for patients. When combined with other sources of information, they can be very useful to clinicians seeking to make a diagnosis.

Cardiac imaging is an active area of biomarker research. Coronary angiography, an invasive procedure requiring catheterization, has long been the gold standard for diagnosing arterial stenosis, but scientists and doctors hope to develop noninvasive techniques. Many believe that cardiac computed tomography (CT) has great potential in this area, but researchers are still attempting to overcome problems related to "calcium blooming," a phenomenon in which calcium deposits interfere with image resolution. Other intravascular imaging techniques involving magnetic resonance imaging (MRI), optical coherence tomography (OCT), and near infrared spectroscopy are also being investigated.

Another new imaging biomarker involves radiolabeled fludeoxyglucose. Positron emission tomography (PET) can be used to measure where in the body cells take up glucose. By tracking glucose, doctors can find sites of inflammation because macrophages there take up glucose at high levels. Tumors also take up a lot of glucose, so the imaging strategy can be used to monitor them as well. Tracking radiolabeled glucose is a promising technique because it directly measures a step known to be crucial to inflammation and tumor growth.

Imaging disease biomarkers by magnetic resonance imaging (MRI)

edit
Main article: molecular imaging

MRI has the advantages of having very high spatial resolution and is very adept at morphological imaging and functional imaging. MRI does have several disadvantages though. First, MRI has a sensitivity of around 10−3 mol/L to 10−5 mol/L which, compared to other types of imaging, can be very limiting. This problem stems from the fact that the difference between atoms in the high energy state and the low energy state is very small. For example, at 1.5 tesla, a typical field strength for clinical MRI, the difference between high and low energy states is approximately 9 molecules per 2 million. Improvements to increase MR sensitivity include increasing magnetic field strength, and hyperpolarization via optical pumping or dynamic nuclear polarization. There are also a variety of signal amplification schemes based on chemical exchange that increase sensitivity.

To achieve molecular imaging of disease biomarkers using MRI, targeted MRI contrast agents with high specificity and high relaxivity (sensitivity) are required. To date, many studies have been devoted to developing targeted-MRI contrast agents to achieve molecular imaging by MRI. Commonly, peptides, antibodies, or small ligands, and small protein domains, such as HER-2 affibodies, have been applied to achieve targeting. To enhance the sensitivity of the contrast agents, these targeting moieties are usually linked to high payload MRI contrast agents or MRI contrast agents with high relaxivities.[31]

Examples

edit

Embryonic

edit 
Embryonic biomarkers are very important to fetuses, as each cell's role is decided through the use of biomarkers. Research has been conducted concerning the use of embryonic stem cells (ESCs) in regenerative medicine. This is because certain biomarkers within a cell could be altered (most likely in the tertiary stage of their formation) to change the future role of the cell, thereby creating new ones. One example of an embryonic biomarker is the protein Oct-4.[32]

Autism

edit 
ASDs are complex; autism is a medical condition with several etiologies caused due to the interactions between environmental conditions and genetic vulnerability. The challenge in finding out the biomarkers related to ASDs is that they may reflect genetic or neurobiological changes that may be active only to a certain point.[33] ASDs show heterogeneous clinical symptoms and genetic architecture, which have hindered the identification of common genetic susceptibility factors. Still, many researches are being done to find out the main reason behind the genetic incomparability.
 
Multiplex analysis of circulating tumor cells using QuantiGene ViewRNA CTC Platform

Cancer

edit

Cancer biomarkers have an extremely high upside for therapeutic interventions in cancer patients. Most cancer biomarkers consist of proteins or altered segments of DNA, and are expressed in all cells, just at higher rates in cancer cells. There has not yet been one, universal tumor biomarker, but there is a biomarker for every type of cancer. These tumor biomarkers are used to track the health of tumors, but cannot serve as the sole diagnostic for specific cancers. Examples of tumoral markers used to follow up cancer treatment are the Carcinoembryonic Antigen (CEA) for colorectal cancer and the Prostate Specific Antigen (PSA) for prostate cancer.[34] In 2014, Cancer research identified Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) as metastasizing tumor biomarkers with special cellular differentiation and prognostic skills. Innovative technology needs to be harnessed to determine the full capabilities of CTCs and ctDNA, but insight into their roles has potential for new understanding of cancer evolution, invasion and metastasis.[35]

Narcolepsy

edit

Type 1 narcolepsy is caused by the loss of approximately 70,000 orexin-releasing neurons in the lateral hypothalamus, resulting in significantly reduced orexin levels in the cerebrospinal fluid (CSF) relative to healthy people.[36] Cerebrospinal orexin can be measured using the lumbar puncture, with CSF orexin levels above 200 pg/ml considered normal.[37] Patients who return a CSF sample with orexin levels below 110 pg/ml are diagnosed with type 1 narcolepsy, even if they do not experience cataplexy.[37] Conversely, patients with normal CSF orexin levels that meet other diagnostic criteria for narcolepsy are diagnosed with type 2 narcolepsy. In the event that a patient who receives an initial diagnosis for type 2 narcolepsy later develops cataplexy or their CSF orexin levels fall below 110 pg/ml, the diagnosis is updated to type 1 narcolepsy.[37] Lateral hypothalamic orexin neurons innervate with noradrenergic and serotoninergic neurons in the ascending reticular activiating system that suppress REM sleep, so loss of these neurons can result in REM sleep-related symptoms like sleep paralysis, hypnagogic hallucinations, and cataplexy.[38][39][40]

Traumatic Brain injury

edit

Traumatic brain injury is a major neurological disorder when the brain is injured by traumatic force such as a bluent trauma or blast over-pressure wave. For the disorders of central nervous system, the neuronal cell body-located Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP) are the first-in-class FDA cleared blood-based biomarker test for mild traumatic brain injury (TBI) with potential brain lesions. These tandem biomarkers were first discovered by Dr. Kevin K. Wang and Dr. Ronald. L. Hayes’ neuroscience laboratories at the McKnight Brain Institute of University of Florida from 2003-2007).[41] Here, traumatic brain injury (TBI) blood-based biomarker test consisted of measuring the levels of neuronal (UCH-L1) and astroglial GFAP to aid in the diagnosis of the presence of cranial lesion(s) among moderate to mild TBI patients that is(are) otherwise only diagnosable with the use of a CT scan of the head.[23] Banyan Biomarkers, Inc., a company co-founded by Drs. Wang, Hayes and Nancy Denslow developed an optimized sandwich chemiluminescent ELISA for UCH-L1/GFAP, termed Brain Trauma Indicator™ (BTI); it contains two kits - one for each of the two biomarkers as chemiluminescence assays on the Synergy 2 Multi-mode Reader (BioTek). These assays were the basis of a pivotal TBI clinical trial called ALERT-TBI (ClinicalTrials.gov #NCT01426919).[42] Over 1,900 adult TBI subjects with a Glasgow Coma Scale of (GCS) 9-15 (mind TBI) were recruited with blood samples drawn within 12 hours of injury to determine if the UCH-L1/GFAP tandem test can aid in the diagnosis of ta presence a cranial lesion that is otherwise only diagnosable with the use of a CT scan of the head. The results of the study show BTI has high sensitivity (97.6%) and negative predictive value (NPV) (99.6%).[43] In February, 2018, FDA cleared the use the BTI for this mild TBI indication.[44][45]

List of Biomarkers

edit

In alphabetic order

Potential disadvantages

edit

Not all biomarkers should be used as surrogate endpoints to assess clinical outcomes. Biomarkers can be difficult to validate and require different levels of validation depending on their intended use. If a biomarker is to be used to measure the success of a therapeutic intervention, the biomarker should reflect a direct effect of that medicine.

See also

edit

References

edit
  1. ^ a b c d Mayeux R (April 2004). "Biomarkers: potential uses and limitations". NeuroRx. 1 (2): 182–188. doi:10.1602/neurorx.1.2.182. PMC 534923. PMID 15717018.
  2. ^ "WHO International Programme on Chemical Safety Biomarkers and Risk Assessment: Concepts and Principles".
  3. ^ "The Biomarkers Consortium". Foundation for the National Institutes of Health. Archived from the original on 2012-01-11. Retrieved 2021-05-31.
  4. ^ "Biomarker Discovery | LCG Biomarker Labs". Archived from the original on 2009-10-25. Retrieved 2010-01-27.
  5. ^ "Biomarker Technology Platforms for Cancer Diagnoses and Therapies". TriMark Publications, LLC. July 2014. Archived from the original on 2020-07-05. Retrieved 2014-08-19.
  6. ^ Loukopoulos P, Thornton JR, Robinson WF (May 2003). "Clinical and pathologic relevance of p53 index in canine osseous tumors". Vet. Pathol. 40 (3): 237–48. doi:10.1354/vp.40-3-237. PMID 12724563.
  7. ^ Loukopoulos P, Mungall BA, Straw RC, Thornton JR, Robinson WF (July 2003). "Matrix metalloproteinase-2 and -9 involvement in canine tumors". Vet. Pathol. 40 (4): 382–94. doi:10.1354/vp.40-4-382. PMID 12824510. S2CID 26506655.
  8. ^ Tevak Z, Kondratovich M, Mansfield E (2010). "US FDA and Personalized Medicine: In vitro Diagnostic Regulatory Perspective". Personalized Medicine. 7 (5): 517–530. doi:10.2217/pme.10.53. PMID 29776248. Archived from the original on 26 July 2024. Retrieved 1 May 2011.
  9. ^ Waaler E (May 2007). "On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939". APMIS. 115 (5): 422–38, discussion 439. doi:10.1111/j.1600-0463.2007.apm_682a.x. PMID 17504400. S2CID 221426678.
  10. ^ Rose HM, Ragan C (May 1948). "Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis". Proc. Soc. Exp. Biol. Med. 68 (1): 1–6. doi:10.3181/00379727-68-16375. PMID 18863659. S2CID 36340687.
  11. ^ Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, et al. (2007). "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis". Arthritis Rheum. 56 (8): 2503–11. doi:10.1002/art.22817. PMID 17665451.
  12. ^ Szodoray P, Szabó Z, Kapitány A, et al. (January 2010). "Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis". Autoimmun Rev. 9 (3): 140–3. doi:10.1016/j.autrev.2009.04.006. hdl:2437/89144. PMID 19427413.
  13. ^ Mathsson L, Mullazehi M, Wick MC, et al. (January 2008). "Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides". Arthritis Rheum. 58 (1): 36–45. doi:10.1002/art.23188. PMID 18163519.
  14. ^ Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al. (2008). "Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy". Arthritis Research & Therapy. 10 (6): R142. doi:10.1186/ar2570. PMC 2656247. PMID 19077182.
  15. ^ Häupl T, Stuhlmüller B, Grützkau A, Radbruch A, Burmester GR (January 2010). "Does gene expression analysis inform us in rheumatoid arthritis?". Ann Rheum Dis. 69 (Suppl 1): i37–42. doi:10.1136/ard.2009.119487. PMID 19995742. S2CID 46118871.
  16. ^ http://www.cancer-biomarkers.com/introduction[permanent dead link‍]
  17. ^ Pharma Matters White Paper: Establishing the standards in biomarker research (2008). Thomson Reuters
  18. ^ Craig-Schapiro R, Fagan AM, Holtzman DM (August 2009). "Biomarkers of Alzheimer's disease". Neurobiol. Dis. 35 (2): 128–40. doi:10.1016/j.nbd.2008.10.003. PMC 2747727. PMID 19010417.
  19. ^ Egerer K, Feist E, Burmester GR (March 2009). "The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens". Dtsch Ärztebl Int. 106 (10): 159–63. doi:10.3238/arztebl.2009.0159. PMC 2695367. PMID 19578391.
  20. ^ Brower V (March 2011). "Biomarkers: Portents of malignancy". Nature. 471 (7339): S19–21. Bibcode:2011Natur.471S..19B. doi:10.1038/471S19a. PMID 21430715. S2CID 4336555.
  21. ^ N. SivaSubramaniam et al. Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases, Brain Research, Volume 1691, 15 July 2018, Pages 75-86, https://doi.org/10.1016/j.brainres.2018.04.017 Archived 2024-07-26 at the Wayback Machine
  22. ^ FDA-NIH Biomarker Working Group F (2016). "BEST (Biomarkers, EndpointS, and other Tools) Resource". NCBI. PMID 27010052. Archived from the original on 26 July 2024. Retrieved 10 December 2023.
  23. ^ a b Wang KK, Kobeissy F, Shakkour Z, Tyndall J (19 Jan 2021). "Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury". Acute Med. Surg. 19, 8(1) (1): e622. doi:10.1002/ams2.622. PMC 7814989. PMID 33510896.
  24. ^ a b Gainor JF, Longo DL, Chabner BA (May 2014). "Pharmacodynamic biomarkers: falling short of the mark?". Clinical Cancer Research. 20 (10). AACR: 2587–2594. doi:10.1158/1078-0432.CCR-13-3132. PMID 24831281. S2CID 153715.
  25. ^ Sarker D, Workman P (2007-01-01). "Pharmacodynamic biomarkers for molecular cancer therapeutics". Advances in Cancer Research. 96: 213–268. doi:10.1016/S0065-230X(06)96008-4. ISBN 9780120066964. PMID 17161682.
  26. ^ Firestein G (2006). "A biomarker by any other name..." Nature Clinical Practice Rheumatology. 2 (635): 635. doi:10.1038/ncprheum0347. PMID 17133243.
  27. ^ Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. (2007). "MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype". Genome Biology. 8 (10): R214. doi:10.1186/gb-2007-8-10-r214. PMC 2246288. PMID 17922911.
  28. ^ "Cellular biomarkers analysis - ImmuneHealth". ImmuneHealth. Archived from the original on 2015-11-25. Retrieved 2015-11-24.
  29. ^ Wang KK, Kobeissy F, Shakkour Z, Tyndall J (19 Jan 2021). "Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury". Acute Med. Surg. 8 (1): e622. doi:10.1002/ams2.622. PMC 7814989. PMID 33510896.
  30. ^ "The Promise of Imaging Biomarkers" (PDF). Thomas Reuters. Archived (PDF) from the original on 2023-07-14. Retrieved 2023-07-14.
  31. ^ Xue S, Qiao J, Pu F, Cameron M, Yang JJ (January 2013). "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdiscip Rev Nanomed Nanobiotechnol. 5 (2): 163–79. doi:10.1002/wnan.1205. PMC 4011496. PMID 23335551.
  32. ^ Nagano K, Yoshida Y, Isobe T (October 2008). "Cell surface biomarkers of embryonic stem cells". Proteomics. 8 (19): 4025–4035. doi:10.1002/pmic.200800073. PMID 18763704. S2CID 7030107.
  33. ^ Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL (2014-08-12). "Biomarkers in autism". Frontiers in Psychiatry. 5: 100. doi:10.3389/fpsyt.2014.00100. PMC 4129499. PMID 25161627.
  34. ^ "Tumor Markers". National Cancer Institute. Archived from the original on 2015-11-25. Retrieved 2015-11-24.
  35. ^ Haber DA, Velculescu VE (June 2014). "Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA". Cancer Discovery. 4 (6): 650–661. doi:10.1158/2159-8290.CD-13-1014. PMC 4433544. PMID 24801577.
  36. ^ Mignot EJ (October 2012). "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics. 9 (4): 739–752. doi:10.1007/s13311-012-0150-9. PMC 3480574. PMID 23065655. At the pathophysiological level, it is now clear that most narcolepsy cases with cataplexy, and a minority of cases (5–30 %) without cataplexy or with atypical cataplexy-like symptoms, are caused by a lack of hypocretin (orexin) of likely an autoimmune origin. In these cases, once the disease is established, the majority of the 70,000 hypocretin-producing cells have been destroyed, and the disorder is irreversible.
  37. ^ a b c Barateau L, Pizza F, Plazzi G, Dauvilliers Y (August 2022). "Narcolepsy". Journal of Sleep Research. 31 (4): e13631. doi:10.1111/jsr.13631. PMID 35624073. Narcolepsy type 1 was called "narcolepsy with cataplexy" before 2014 (AASM, 2005), but was renamed NT1 in the third and last international classification of sleep disorders (AASM, 2014). ... A low level of Hcrt-1 in the CSF is very sensitive and specific for the diagnosis of NT1. ... All patients with low CSF Hcrt-1 levels are considered as NT1 patients, even if they report no cataplexy (in about 10–20% of cases), and all patients with normal CSF Hcrt-1 levels (or without cataplexy when the lumbar puncture is not performed) as NT2 patients (Baumann et al., 2014). ... If cataplexy appears over time in a NT2 patient (some- times many years later), or if a Hcrt-1 level is below 110 pg ml (even without cataplexy), the condition is reclassified as NT1.
  38. ^ Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 10: Neural and Neuroendocrine Control of the Internal Milieu". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). New York: McGraw-Hill Medical. pp. 456–457. ISBN 9780071827706. More recently, the lateral hypothalamus was also found to play a central role in arousal. Neurons in this region contain cell bodies that produce the orexin (also called hypocretin) peptides (Chapter 6). These neurons project widely throughout the brain and are involved in sleep, arousal, feeding, reward,aspects of emotion, and learning. In fact, orexin is thought to promote feeding primarily by promoting arousal. Mutations in orexin receptors are responsible for narcolepsy in a canine model, knockout of the orexin gene produces narcolepsy in mice, and humans with narcolepsy have low or absent levels of orexin peptides in cerebrospinal fluid (Chapter 13). Lateral hypothalamus neurons have reciprocal connections with neurons that produce monoamine neurotransmitters (Chapter 6).
  39. ^ Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 13: Sleep and Arousal". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). McGraw-Hill Medical. p. 521. ISBN 9780071827706. The ARAS consists of several different circuits including the four main monoaminergic pathways discussed in Chapter 6. The norepinephrine pathway originates from the LC and related brainstem nuclei; the serotonergic neurons originate from the RN within the brainstem as well; the dopaminergic neurons originate in the ventral tegmental area (VTA); and the histaminergic pathway originates from neurons in the tuberomammillary nucleus (TMN) of the posterior hypothalamus. As discussed in Chapter 6, these neurons project widely throughout the brain from restricted collections of cell bodies. Norepinephrine, serotonin,dopamine, and histamine have complex modulatory functions and, in general, promote wakefulness. The PT in the brainstem is also an important component of the ARAS. Activity of PT cholinergic neurons (REM-on cells) promotes REM sleep, as noted earlier. During waking, REM-on cells are inhibited by a subset of ARAS norepinephrine and serotonin neurons called REM-off cells.
  40. ^ Mahlios J, De la Herrán-Arita AK, Mignot E (October 2013). "The autoimmune basis of narcolepsy". Current Opinion in Neurobiology. 23 (5): 767–773. doi:10.1016/j.conb.2013.04.013. PMC 3848424. PMID 23725858.
  41. ^ "Banyan Biomarkers: Perfect storm of collaboration". University of Florida News. Archived from the original on 26 July 2024. Retrieved 10 December 2023.
  42. ^ "Evaluation of Biomarkers of Traumatic Brain Injury (ALERT-TBI)". classic.clinicaltrials.gov. Archived from the original on 26 July 2024. Retrieved 10 December 2023.
  43. ^ Bazarian JJ, Biberthaler P, Welch RD, et a (1 September 2018). "Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study". Lancet Neurology. 17 (9): 782–789. doi:10.1016/S1474-4422(18)30231-X. PMID 30054151.
  44. ^ "EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR Banyan Brain Trauma Indicator DEN170045" (PDF). FDA. Retrieved 10 December 2023.
  45. ^ "FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults". FDA New Release. 24 March 2020. Archived from the original on 9 September 2018. Retrieved 10 December 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Biomarker_(medicine)&oldid=1257523928"